Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial

References

• Hoster E, Dreyling M, Klapper W, et al A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209–1213.
   PubMed Web of Science ®Google Scholar
• Goy A, Feldman T. Expanding therapeutic options in mantle cell lymphoma. Clin Lymphoma Myeloma 2007;7(Suppl. 5):S184–S191.
   PubMedGoogle Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• Bogner C, Peschel C, Decker T. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma 2006;47:195–205.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, et al Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131–144.
   PubMed Web of Science ®Google Scholar
• Mulligan G, Mitsiades C, Bryant B, et al Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177–3188.
   PubMed Web of Science ®Google Scholar
• Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88–95.
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Petzoldt C, Holler S, et al The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006;107:3407.
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, et al Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29–38.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Budel LM, Skolnik J, et al Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000;95:619–626.
   PubMed Web of Science ®Google Scholar
• Letestu R, Ugo V, Valensi F, et al Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. Leukemia 2004;18:953–961.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, et al Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–2387.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Moskowitz C, Maragulia J, Portlock CS, Teruya-Feldstein J. Sequential chemotherapy followed by high dose therapy and autologous stem cell rescue for mantle cell lymphoma: impact of MIB-1 on outcome abstract.. Blood 2008;112(Suppl. 1):1287a (Abstract 3759).
   Google Scholar
• Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:30–36.
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Niedzwiecki D, Compton CC, et al Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27:1814–1821.
   PubMed Web of Science ®Google Scholar
• Izzo JG, Malhotra U, Wu TT, et al Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 2007;16:1200–1205.
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Andre F, Sagan C, et al Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2809–2815.
   PubMed Web of Science ®Google Scholar
• Hartmann E, Fernandez V, Moreno V, et al Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008;26:4966–4972.
   PubMed Web of Science ®Google Scholar
• Martinez N, Camacho FI, Algara P, et al The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003;63:8226–8232.
   PubMed Web of Science ®Google Scholar
• Kane RC, Dagher R, Farrell A, et al Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291–5294.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Jung SH, Lai R, et al Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008;49:2081–2090.
   PubMed Web of Science ®Google Scholar
• Cecconi D, Zamo A, Bianchi E, et al Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 2008;8:4495–4506.
   PubMed Web of Science ®Google Scholar
• Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006;107:4540–4548.
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, et al Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712–716.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, et al Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717–721.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, et al Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B cell lymphoma. Blood 2009;113:6069–6076.
   PubMed Web of Science ®Google Scholar